{{Rsnum
|rsid=471767
|Gene=PGR
|Chromosome=11
|position=101034566
|Orientation=plus
|GMAF=0.2264
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=PGR
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 46.9 | 45.1 | 8.0
| HCB | 89.8 | 9.5 | 0.7
| JPT | 89.4 | 9.7 | 0.9
| YRI | 50.3 | 42.0 | 7.7
| ASW | 36.8 | 50.9 | 12.3
| CHB | 89.8 | 9.5 | 0.7
| CHD | 91.7 | 7.4 | 0.9
| GIH | 43.6 | 44.6 | 11.9
| LWK | 59.8 | 33.6 | 6.5
| MEX | 70.7 | 27.6 | 1.7
| MKK | 49.4 | 43.6 | 7.1
| TSI | 39.2 | 48.0 | 12.7
| HapMapRevision=28
}}[http://www.medpagetoday.com/MeetingCoverage/SMFM/12729 news]  The effectiveness of [[17 alpha-hydroxyprogesterone caproate]] for prevention of recurrent preterm birth is influenced by SNPs.

Black women
*[[rs471767]] homozygous for the major allele treatment significantly reduced the rate of preterm birth.
*[[rs578029]] who had a least one copy of the major allele, treatment significantly reduced in preterm birth

non-black women
*a least one copy of the minor allele of [[rs503362]] had a significant reduction with treatment
*with at least one copy of the minor allele of [[rs666553]] had a significant reduction in very preterm birth

{{PMID Auto
|PMID=19382201
|Title=Association of the progesterone receptor gene with endometrial cancer risk in a Chinese population
|OA=1
}}

{{PMID Auto
|PMID=21148628
|Title=Progesterone receptor gene variants and risk of endometrial cancer
|OA=1
}}

{{PMID Auto
|PMID=21600550
|Title=Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate
|OA=1
}}

{{PMID Auto
|PMID=20308837
|Title=Progesterone receptor genotype, family history, and spontaneous preterm birth.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}